Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2312  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
Read this article

 


    Article Cited by others

CASE REPORT

Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India

Ramasamy Kesavan, Narayan Sunil K, Chanolean Shashindran, Chandrasekaran Adithan

Year : 2007| Volume: 55| Issue : 4 | Page no: 408-409

   This article has been cited by
 
1 Pharmacogenetics of adverse reactions to antiepileptic drugs
I. Fricke-Galindo,H. Jung-Cook,A. LLerena,M. López-López
Neurología (English Edition). 2017;
[Pubmed]  [Google Scholar] [DOI]
2 Farmacogenética de reacciones adversas a fármacos antiepilépticos
I. Fricke-Galindo,H. Jung-Cook,A. LLerena,M. López-López
Neurología. 2015;
[Pubmed]  [Google Scholar] [DOI]
3 CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco,Emilio Perucca
Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(8): 1269
[Pubmed]  [Google Scholar] [DOI]
4 Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes
Yoshiaki Yamamoto,Yukitoshi Takahashi,Katsumi Imai,Kou Miyakawa,Hiroko Ikeda,Yuki Ueda,Tokito Yamaguchi,Hirosato Nasu,Hideyuki Ohtani,Hideo Shigematsu,Yoshiyuki Kagawa,Yushi Inoue
Therapeutic Drug Monitoring. 2015; 37(2): 229
[Pubmed]  [Google Scholar] [DOI]
5 Farmacogenetica dei farmaci antiepilettici
M.W. Mann,S. Chhun,G. Pons
EMC - Neurologia. 2014; 14(4): 1
[Pubmed]  [Google Scholar] [DOI]
6 Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
K E Caudle,A E Rettie,M Whirl-Carrillo,L H Smith,S Mintzer,M T M Lee,T E Klein,J T Callaghan
Clinical Pharmacology & Therapeutics. 2014;
[Pubmed]  [Google Scholar] [DOI]
7 Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis
Tanima De,Rita Christopher,Dindagur Nagaraja
Thrombosis Research. 2014; 133(5): 729
[Pubmed]  [Google Scholar] [DOI]
8 Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs
Chiara Piana,Natalicia de Jesus Antunes,Oscar Della Pasqua
Expert Opinion on Drug Metabolism & Toxicology. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Pharmacogenetics and antiepileptic drug metabolism: Implication of genetic variants in cytochromes P450 [Farmacogenética y metabolismo de fármacos antiepilépticos: Implicación de variantes genéticas en citocromos P1450]
Saldaña-Cruz, A.M. and Sánchez-Corona, J. and Márquez de Santiago, D.A. and García-Zapién, A.G. and Flores-Martínez, S.E.
Revista de Neurologia. 2013; 56(9): 471-479
[Pubmed]  [Google Scholar]
10 Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients
Phabphal, K. and Geater, A. and Limapichart, K. and Sathirapanya, P. and Setthawatcharawanich, S.
Seizure. 2013; 22(2): 103-108
[Pubmed]  [Google Scholar]
11 Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
Ekta Varshney,Nilanjan Saha,Monika Tandon,Vikesh Shrivastava,Shakir Ali
European Journal of Drug Metabolism and Pharmacokinetics. 2013;
[Pubmed]  [Google Scholar] [DOI]
12 The association between CYP 2C9 polymorphism and bone health
Kanitpong Phabphal,Alan Geater,Kitti Limapichat,Pornchai Sathirapanya,Suwanna Setthawatcharawanich,Rattana Leelawattana
Seizure. 2013; 22(9): 766
[Pubmed]  [Google Scholar] [DOI]
13 Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
P Dorado,E López-Torres,E M Peñas-LLedó,J Martínez-Antón,A LLerena
The Pharmacogenomics Journal. 2013; 13(4): 359
[Pubmed]  [Google Scholar] [DOI]
14 From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
Bob Wilffert,Jesse Swen,Hans Mulder,Daan Touw,Anke-Hilse Maitland-Van der Zee,Vera Deneer
International Journal of Clinical Pharmacy. 2013; 35(3): 369
[Pubmed]  [Google Scholar] [DOI]
15 Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients
Kanitpong Phabphal,Alan Geater,Kitti Limapichart,Pornchai Sathirapanya,Suwanna Setthawatcharawanich
Seizure. 2013; 22(2): 103
[Pubmed]  [Google Scholar] [DOI]
16 Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients
Thakkar, A.N. and Bendkhale, S.R. and Taur, S.R. and Gogtay, N.J. and Thatte, U.M.
Neurology India. 2012; 60(6): 577-580
[Pubmed]  [Google Scholar]
17 Genetic basis of phase II drug-metabolizing enzymes in antiepileptic drug toxicity
Grover, S. and Kukreti, R.
Pharmacogenomics. 2012; 13(5): 521-522
[Pubmed]  [Google Scholar]
18 Research Highlights
Sandeep Grover, Ritushree Kukreti
Pharmacogenomics. 2012; 13(5): 519
[HTML Full text]  [Google Scholar] [DOI]
19 From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
Bob Wilffert, Jesse Swen, Hans Mulder, Daan Touw, Anke-Hilse Maitland-Van der Zee, Vera Deneer
International Journal of Clinical Pharmacy. 2011; 33(1): 3
[HTML Full text]  [Google Scholar] [DOI]
20 Pharmacogenomics and epilepsy: the road ahead
Gianpiero L Cavalleri, Mark McCormack, Saud Alhusaini, Elijah Chaila, Norman Delanty
Pharmacogenomics. 2011; 12(10): 1429
[HTML Full text]  [Google Scholar] [DOI]
21 Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
Junji Saruwatari,Takateru Ishitsu,Kazuko Nakagawa
Pharmaceuticals. 2010; 3(8): 2709
[Pubmed]  [Google Scholar] [DOI]
22 Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy
Saruwatari, J. and Ishitsu, T. and Nakagawa, K.
Pharmaceuticals. 2010; 3(8): 2709-2732
[Pubmed]  [Google Scholar]
23 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients
Ramasamy Kesavan, Sunil K. Narayan, Chandrasekaran Adithan
European Journal of Clinical Pharmacology. 2010; 66(7): 689
[HTML Full text]  [Google Scholar] [DOI]
24 The tough fate of prototype drugs. Activation problems of the angiotensin receptor blocker, losartan [Der schwere stand der leitsubstanzen aktivierungsprobleme des angiotensin-rezeptor-antagonisten losartan]
Petersen, K.-U.
Nieren- und Hochdruckkrankheiten. 2009; 38(11): S21-S32
[Pubmed]  [Google Scholar]

 

Online since 20th March '04
Published by Wolters Kluwer - Medknow